Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis

Figure 4

Effect of roxithromycin on inflammatory marker in sputum of patients after 6 months of treatment. (a) Effect of roxithromycin on induced sputum IL-8 concentration (μg/L) in patients with NCFB after 6 months of treatment (); (b) effect of roxithromycin on induced sputum NE concentration (ng/mL) in patients with NCFB after 6 months of treatment (); (c) effect of roxithromycin on induced sputum MMP-9 concentration (μg/L) in patients with NCFB after 6 months of treatment (); (d) there were no significant changes of activity scores and impact scores in either group (); (e) effect of roxithromycin on induced sputum MMP9/TIMP-1 in patients with NCFB after 6 months of treatment (); (f) effect of roxithromycin on induced sputum HA concentration (ng/mL) in patients with NCFB after 6 months of treatment (); (g) effect of roxithromycin on type IV collagen concentration (μg/L) in patients with NCFB after 6 months of treatment ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)